Condition
Poorly Differentiated Thyroid Carcinoma
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
Early P 1 (1)
P 1 (1)
P 2 (1)
Trial Status
Recruiting2
Unknown1
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07485569Phase 1Not Yet Recruiting
Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial
NCT07068542Not ApplicableRecruiting
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
NCT06639191Early Phase 1Recruiting
[177Lu]Lu-AKIR001 First-in-human Study
NCT03387943Phase 2UnknownPrimary
PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma
Showing all 4 trials